212.4: Tetramethylpyrazine Alleviates Liver Ischemia-reperfusion Injury of Transplantation in Rat Model From Donation After Cardiac Death via Activation of PPARγ/Nrf2 Signaling Pathway
Fu Zhen,Fan Lin,Ye Qi Fa
DOI: https://doi.org/10.1097/01.tp.0000885336.02150.6b
2022-01-01
Transplantation
Abstract:Background: 45% of Liver grafts from donation after cardiac death (DCD) are discarded for transplantation because of their poor tolerance to ischemia reperfusion injury (IRI). Based on the previous research, tetramethylpyrazine(TMP) could reduce liver IRI of DCD in rats model, but the molecular mechanisms are unclear. Objective: This work aims to investigate the molecular mechanisms, it would to provide effective ideas for clinical evaluation and repair of DCD liver. Methods: The DCD model was established by cardiac arrest caused by asphyxia. The rat liver was induced 30min of in-situ warm ischemia and then to be placed in 4℃ UW solution for 3h,followed by 1h hypothermic oxygenated machine perfusion (HOPE). TMP (50mg/kg) was injected by dorsal vein of the penis in rats for 1h before DCD. PPARγ agonist Rosiglitazone and inhibitor GW9662 were administered 30min before DCD modeling, respectively.The liver of DCD of each group received orthotopic liver transplantation. Blood and tissue samples were collected 6h after the operation. The levels of ALT and AST in serum were detected by automatic biochemical analyzer, the levels of IL-1β and TNF-a in serum were detected by ELISA, and the morphological changes of liver were observed by HE staining. The protein expressions of PPARγ, NRF2, KEAP1, NQO1 and HO-1 were detected by Western bolting, and the mRNA levels of TLR-4, TRIF and MYD88 were detected by PCR. The postoperative survival rate was evaluated. Results: Serum ALT and AST levels in HOPE group were 4094±778.156 U/L and 6869.6±1324.486 U/L, respectively, 6 hours after liver transplantation. Serum ALT and AST in Rosiglitazone group were 3783.2±851.737U/L and 4773.6±1105.611 U/L, respectively, without statistical significance (P =0.632, P =0.016). The ALT and AST of PPARγ inhibitor GW9662 group were 8638.2±1886.557 U/L and 8321±2099.721U/L, respectively (P <0.01). The serum levels of IL-6 and TNF-a in Rosiglitazone group were significantly lower than those in PPARγ inhibitor GW9662 group (P <0.05). The expressions of PPARγ, NRF2, KEAP1, NQO1 and HO-1 in DCD liver were found to be the lowest in GW9662 group (P <0.05). Therefore, we inferred that HOPE can enhance the ability of TMP to activate PPARγ, and then to stimulate the expression of Nrf2 to induce transcription and activation of downstream.The expression of TLR-4 and TRIF decreased in the Rosiglitazone group (P <0.05), while the expression of MYD88 did not change significantly, suggesting that the enhanced anti-immune response of HOPE may be related to the activation of PPARγ by TMP and the inhibition of TLR-4/TRIF pathway. Compared with the 1-week survival rate, the survival rate of the normal liver group was 100% (6/6), the survival rate of the CS and HOPE groups was 50% (3/6) and 83% (5/6), respectively. The main causes of death within 24 hours were pulmonary embolism and postoperative hypothermia, and the main cause of death within 7 days was biliary complications. Conclusion: HOPE enhanced the protective effect of TMP on improving the quality of DCD donor-derived liver transplantation, and its repair mechanism may be related to NRF2/PPARγ and TLR-4/TRIF signals, providing a new trail for DCD donor-derived liver. Key words：liver transplantation; hypothermic oxygenated machine perfusion; donation after cardiac death; tetramethylpyrazine; PPARγ; NRF2. Science and Technology Innovation Cultivation Fund of Zhongnan Hospital of Wuhan University(No.znpy2019041). National Natural Science Foundation of China (Grant No. 81970548). Medical Science Advancement Program (Youth Scholars) of Wuhan University (Grant No. TFZZ2018035).